Animoca Brands动态：合并暂停，纳斯达克上市推迟
BiFu Editorial · 2026-09-23 · 阅读 3 分钟
目录
根据三个独立信源确认，Animoca Brands已暂停与Currenc Group的反向合并谈判，其纳斯达克上市计划因此推迟，但公司仍致力于未来公开上市。
根据三个独立信源确认，Animoca Brands已暂停与Currenc Group的反向合并谈判，其纳斯达克上市计划因此推迟，但公司仍致力于未来公开上市。共同的变化是，原本将使Animoca上市的特定交易被叫停，影响了Animoca Brands、Currenc Group及董事长萧逸。运营影响是上市时间表无限期暂停，未确认任何替代方案或日期。
已确认的变化：反向合并暂停
CoinDesk报道，Animoca Brands推迟了IPO计划，并暂停了与Currenc的合并谈判，该交易原计划让Animoca拥有合并后公司95%的股权。Cointelegraph补充称，此次暂停使纳斯达克上市计划搁浅，但Animoca表示仍致力于在主要交易所上市。The Block直接引用了董事长萧逸的话，称“企业敏捷性必须优先于”Currenc交易。
所有三个信源都确认了反向合并谈判的暂停以及萧逸所述的缘由。受影响方包括Animoca Brands、Currenc Group以及任何预期合并实体将在纳斯达克交易的股东。运营影响是上市流程被叫停，Animoca目前没有确认的公开市场时间表。
尚未核实的内容
仍需通过原始文件核实的是，Currenc交易是永久终止还是仅暂停。CoinDesk关于95%持股计划的报道未得到其他两家媒体的独立证实，也没有监管文件或签署的条款清单来验证该数字。下一步需对照双方最初的合并协议或任何公司文件进行核实。
在该文件出现之前，已确认的事实仅是Currenc合并谈判暂停。Animoca是否会选择传统IPO、其他SPAC合作伙伴或直接上市，目前仍未核实，且尚未公布任何修订后的时间表或替代方案。
谁受到影响
此次暂停直接影响Animoca Brands、董事长萧逸、Currenc Group以及任何预期合并实体将在美国交易所开始交易的投资者或市场参与者。对Currenc Group而言，暂停意味着失去其计划的合并目标，需要寻找新的业务合并机会或向投资者返还资金。对Animoca Brands而言，与Currenc交易相关的特定纳斯达克上市路径现已停滞。
共同的运营影响是Animoca已知的上市路径出现重大延迟，公司目前没有确认的IPO时间表或地点。董事长萧逸关于“企业敏捷性必须优先于”交易的声明确认了战略转向，但未提供后备方案。
为何重要
反向合并谈判的暂停是三个报道中均确认的变化，但更广泛的上市雄心仍然存在。下一步需核实的是任何一方首次提及具体交易所或申请窗口的官方声明。在该文件交叉验证之前，应将暂停视为已确认，而后续路径视为未核实。
参考资料
- https://www.coindesk.com/business/2026/09/22/animoca-brands-delays-ipo-plans-suspends-merger-talks-with-currenc
- https://cointelegraph.com/news/animoca-currenc-merger-delaying-nasdaq-debut
- https://www.theblock.co/news/business/2026-09-21-animoca-brands-suspends-merger-deal-415991
阅读更多 BiFu 内容
根据三个独立信源确认，Animoca Brands已暂停与Currenc Group的反向合并谈判，其纳斯达克上市计划因此推迟，但公司仍致力于未来公开上市。
相关文章
特朗普最新动态：柴油禁令、贸易协议与下一步需核实事项
近期五个独立来源的特朗普动态显示能源、贸易和金融政策转向。最具体变化：特朗普总统支持柴油出口禁令，据MarketWatch报道，决定将“很快以某种方式”做出。同时，财政部长确认政府正在研究禁令可行性，共和党议员在中期选举前呼吁行动。这些举措直接影响农民、卡车司机和能源市场。
2026-09-23 · 阅读 5 分钟
Viking Therapeutics 最新进展：新规则与新审核机制上线
2026年9月22日，Viking Therapeutics 凭借其双重 GLP-1/GIP 受体激动剂 VK2735 的肥胖症药物数据股价大涨，而礼来和诺和诺德股价下跌。VK2735 的关键维持期研究数据预计于 2026 年第三季度公布，具体数据性质及市场份额变化尚未得到证实。.
2026-09-23 · 阅读 4 分钟
风险警告
Trading foreign exchange, contracts for difference, over-the-counter derivatives, margin products, and other leveraged financial instruments involves a high level of risk and may not be suitable for all clients. These products can result in losses that may exceed your initial deposit, depending on the product terms, account settings, and applicable legal protections. You should not trade unless you fully understand the nature of the products, the risks involved, and the extent of your exposure. When trading derivative products, you do not own or have any rights to the underlying asset.
The information provided on this website is general in nature and does not take into account your investment objectives, financial situation, trading experience, or particular needs. Nothing on this website should be construed as personal financial advice, investment advice, an offer, invitation, solicitation, recommendation, or inducement to buy, sell, subscribe for, or dispose of any financial product or service.
All market commentary, educational materials, research content, platform information, and other materials published on this website are provided for general information and reference purposes only. Past performance, historical data, examples, forecasts, or simulated results are not reliable indicators of future performance.
Access to Bifu Markets’ products and services is not available in all jurisdictions. We do not open accounts for residents of certain countries and jurisdictions, including but not limited to the United States, Australia, Canada, and the Democratic People's Republic of Korea.
By accessing this website, you confirm that you are doing so on your own initiative and that you are responsible for ensuring that your use of this website and any services provided by Bifu Markets complies with the laws and regulations applicable to you in your jurisdiction.
Bifu is operated by Bifu Markets (Pty) Ltd.
Registered address: Norwich Place West, 2nd Floor, Cnr 5th and Norwich, Sandown, Sandton, Gauteng, South Africa.